Humana price target lowered to $234 from $245 at Barclays

Barclays analyst Andrew Mok lowered the firm’s price target on Humana (HUM) to $234 from $245 and keeps an Equal Weight rating on the shares. If company “executes flawlessly,” $14 of earnings per share next year is possible, the analyst tells investors in a research note. However, the firm says Humana’s “execution risk is real.” It models break-even individual Medicare Advantage margins and $11 in EPS.